Search results for "antiplatelets"

showing 3 items of 3 documents

Antiplatelet treatment in ischemic stroke treatment.

2009

Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity through a variety of mechanisms. Antithrombotic agents are effective in the secondary prevention of ischemic strokes. Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot. Immediate treatment with antiplatelet drugs such as aspirin may prevent new clots from forming and hence improve recovery after stroke. Several studies have evaluated the role of one antiplatelet agent, aspirin, in reducing stroke severity. The International Stroke Trial (IST) of 20,000 patients with acute stroke from other countries. In thi…

medicine.medical_specialtySettore MED/09 - Medicina InternaTiclopidineBrain IschemiaInternal medicineDrug DiscoveryAntithromboticmedicineHumanscardiovascular diseasesPlatelet activationTiclopidineStrokeAspirinAspirinbusiness.industryGeneral Medicinemedicine.diseaseClopidogrelSurgeryClopidogrelStrokemedicine.anatomical_structureToxicityCardiologyantiplatelets strokeprevention treatmentbusinessPlatelet Aggregation Inhibitorsmedicine.drugArteryCurrent topics in medicinal chemistry
researchProduct

Antiplatelets in stroke prevention

2014

Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic st…

medicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINEPrimary preventionSecondary PreventionmedicineAnimalsHumanscardiovascular diseasesMyocardial infarctionIntensive care medicineStrokeCause of deathPharmacologySecondary preventionAspirinAspirinbusiness.industrymedicine.diseasePrimary PreventionStrokeCardiovascular DiseasesPhysical therapyPlatelet aggregation inhibitorantiplatelets Stroke preventionCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - …

2008

Peripheral Vascular DiseasesLegtrainingTiclopidineAspirinAcetylsalicylic acidanticoagulant agentantithrombocytic agentconsensus document; intermittent claudicatio; training; antiplatelets' therapyintermittent claudicatioIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareClopidogrelantiplatelets' therapyIschemiaDisease ProgressionExercise TestHumansCarotid StenosisUltrasonography Doppler Colorconsensus documentPlatelet Aggregation Inhibitors
researchProduct